Serum CA-125 as a guideline for the timing of a second-look operation and second-line treatment in ovarian cancer
- 1 January 1988
- journal article
- research article
- Published by Springer Nature in Archiv für Gynäkologie
- Vol. 243 (2) , 91-99
- https://doi.org/10.1007/bf00932974
Abstract
In the assessment of response to treatment of ovarian cancer patients, clinical examination is unreliable in detecting small tumor masses. The second-look laparotomy is therefore an accepted procedure. The optimal timing of second-look laparotomy, however, is uncertain. We therefore examined the usefulness of serial serum CA-125 estimations in the timing of second-look laparotomies in 33 patients suffering from ovarian cancer. Increasing CA-125 concentrations were always followed by relapses or progressive disease, whereas decreasing serum concentrations indicated response to treatment. In future we propose to perform second-look laparotomies when CA-125 levels have declined to a steady plateau and to star a secondary treatment when CA-125 levels start to rise again.Keywords
This publication has 34 references indexed in Scilit:
- Stellenwert der radikalen Chirurgie bei der Behandlung des OvarialkarzinomsArchiv für Gynäkologie, 1987
- The potential for optimal (⩽ 2 cm) cytoreductive surgery in advanced ovarian carcinoma at a tertiary medical center: A prospective studyGynecologic Oncology, 1986
- A review of second-look laparotomy for ovarian cancerGynecologic Oncology, 1986
- Longitudinal study of CEA and CA125 in ovarian cancerGynecologic Oncology, 1985
- Erfahrungen mit CA 125, einem Tumormarker für maligne epitheliale Ovarialtumoren*Geburtshilfe und Frauenheilkunde, 1985
- Die Chemotherapie als Primärtherapie beim nicht radikal operierten OvarialkarzinomOncology Research and Treatment, 1985
- Die operative Tumorreduktion beim ausgedehnten OvarialkarzinomOncology Research and Treatment, 1985
- Cisplatin beim Ovarialkarzinom: wieviel und wie lange?Deutsche Medizinische Wochenschrift (1946), 1985
- Treatment of advanced ovarian cancer with combination chemotherapy using cyclophosphamide, adriamycin and cis‐platinumBJOG: An International Journal of Obstetrics and Gynaecology, 1984
- Alternating multiagent chemotherapy for advanced ovarian cancerJournal of Surgical Oncology, 1983